Sunday, 4 October 2026European Markets

NEW SOURCES ENERGY Stock Bullish Momentum With A 17% Rise In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of NEW SOURCES ENERGY (AEX-Index: NSE.AS) jumped by a staggering 17.65% in 5 sessions from €0.02 to €0.02 at 05:08 EST on Wednesday, following the last session's upward trend. AEX-Index is rising 0.13% to €774.48, following the last session's upward trend.

About NEW SOURCES ENERGY

New Sources Energy N.V. develops, operates, exploits, and invests in projects that generates electricity using renewable energy sources. The company was formerly known as Management Share NV and changed its name to New Sources Energy N.V. in July 2011. New Sources Energy N.V. is headquartered in Amersfoort, the Netherlands.

Volatility

NEW SOURCES ENERGY's last week, last month's, and last quarter's current intraday variation average was a negative 9.92%, a negative 3.77%, and a positive 10.57%.

NEW SOURCES ENERGY's highest amplitude of average volatility was 15.48% (last week), 8.50% (last month), and 10.57% (last quarter).

Volume

Today's last reported volume for NEW SOURCES ENERGY is 43550 which is 70.01% below its average volume of 95213.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com